Login to Your Account



In Tough Times, Corporate VCs Could Pick Up Financing Slack

By Jennifer Boggs


Monday, January 26, 2009
In Hydra Biosciences Inc.'s recent $22 million Series D round, three of its seven venture capital investors were corporate investing arms, a trend that's likely to increase if VC money becomes as hard to find as many industry experts are predicting.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription